Moreover, only 7.7% of the participants stated they would prescribe glucagon-like peptide-1 (GLP-1) receptor agonist for patients with obesity and PCOS for weight loss (Fig. 3a). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.